Enlight spins off Entrega for oral biologic drug delivery

In-PharmaTechnologist.com is reporting that Boston-based Enlight Biosciences has formed a new company, Entrega, which will focus on oral drug delivery techniques. The new company will use its delivery platform to develop oral versions of biologic drugs that now require injections, including insulin and antibodies.

Enlight's Baruch Harris told In-PharmaTechnologist that that biologic drugs currently provide more than $120 billion in annual revenues, but most require injections. "The ability to deliver biologics orally would address a significantly unmet need for patients and allow much easier treatment paradigms for many conditions that need to be treated with biologics," Harris told the publication, adding that Entrega's drug delivery technology is capable of oral delivery of a range of peptides and proteins.

Harris says that barriers in perception remain, telling In-PharmaTechnologist that "scientific and technical challenges have been so great that most people in the industry are understandably cautious about the success of any one technology."

- read the full story from In-PharmaTechnologist.com

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.